Hunan New Wellful Co., Ltd. Class A

Hunan New Wellful Co., Ltd. Class A

SSSE:600975
4.76
CNY
-0.17
(-3.45%)
-1.78EPS
6.49BMarket Cap
Mar 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.49
2.79
2.15
2.58
2.69
2.85
3.37
4.14
3.63
5.8
4.82
5.38
5.8
4.94
Basic EPS, GAAP
0.03
-0.11
0.06
0.3
0.07
-0.05
0.1
0.43
-0.44
-0.09
-1.03
0.03
-0.7
-1.73
Free Cash Flow per Basic Share
-0.41
-0.29
0.05
0.16
0.17
-0.12
-0.2
-0.13
-1.42
-0.25
-0.83
0.55
0.41
- -
Dividend per Share
0.06
0.05
0.03
0.05
0.12
0.1
0.01
0.05
0.17
0.09
0.07
0.06
0.04
0.04
Book Value per Share
1.18
1.09
1.64
1.87
1.84
1.69
1.79
2.17
3.06
3.35
2.37
2.4
1.73
0.67
Tangible Book Value per Share
1.02
0.93
1.53
1.75
1.72
1.57
1.67
2.06
2.92
3.14
2.24
2.25
1.59
0.53
Basic Weighted Avg Shares
454
466
616
655
642
717
633
657
673
863
1,168
1,311
1,252
1,251
Sales/Revenue/Turnover
1,130
1,302
1,326
1,691
1,724
2,041
2,130
2,724
2,444
5,005
5,632
7,045
7,258
6,184
Operating Margin (%)
-2.19
-5.79
0.39
10.07
3.15
-1.37
3.77
10.93
-2.47
2.62
-13.07
5.93
-3.72
-16.14
Depreciation Expense
34
45
50
59
62
67
69
60
312
580
923
954
923
- -
Net Income, GAAP
14
-49
37
197
45
-36
63
283
-296
-78
-1,203
39
-876
-2,168
Effective Tax Rate (%)
6.06
- -
- -
- -
14.21
- -
3.12
- -
- -
- -
- -
5.1
- -
- -
Profit Margin (%)
1.21
-3.76
2.79
11.62
2.61
-1.76
2.97
10.38
-12.12
-1.55
-21.37
0.56
-12.08
-35.06
Working Capital
302
150
635
749
697
558
470
508
818
420
285
715
-286
-454
LT Debt
200
200
176
146
106
62
- -
715
2,905
5,074
6,014
6,152
5,209
5,822
Total Equity
622
602
1,130
1,297
1,270
1,162
1,230
1,488
2,708
2,919
3,166
3,213
2,339
989
Return on Invested Capital (%)
-3.44
- -
- -
- -
2.64
- -
5.59
- -
- -
- -
- -
0.58
- -
- -
Return on Capital (%)
2.93
- -
- -
- -
4.06
- -
4.86
- -
- -
- -
- -
0.95
- -
- -
Return on Common Equity (%)
2.47
-9.21
4.68
17.15
3.7
-3.11
5.58
21.9
-15.28
-3.01
-42.33
1.31
-33.8
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,526
1,210
1,879
LT Borrowings
1,412
1,888
1,669
LT Finance Leases
4,265
4,251
4,153
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,250
1,250
1,250
Market Capitalization
6,686
5,386
6,486

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,815
2,776
2,505
Cash, Cash Equivalents & STI
782
608
658
Accounts Receivable, Net
108
95
87
Inventories
1,682
1,835
1,539
Total Current Liabilities
2,790
2,451
2,959
Payables & Accruals
- -
- -
- -
ST Debt
1,526
1,210
1,879
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.35%
14.49%
-27.21%
Free Cash Flow
118.75%
220.47%
-28.65%
Net Income, GAAP
-101.71%
-252.42%
-2,328.98%
Sales/Revenue/Turnover
21.53%
27.03%
3.02%
Total Cash Common Dividend
66.37%
42.1%
-32.79%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,430
1,803
2,038
1,774
7,045
2025
1,863
1,825
- -
1,868
7,258
2026
1,565
1,268
1,483
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
0.01
0.2
0.03
0.03
2025
0.02
0.02
- -
-0.69
-0.7
2026
-0.3
-0.29
-0.46
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.01
0.06
2025
0.02
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Yong Sheng Zhu
Full Time Employees
5,310
Sector
Consumer non-durables
Industry
Food: meat/fish/dairy
Address
First Avenue Changsha HU China 410005
IPO Date
Jun 9, 2004
Website
newwf.com
Business
Hunan New Wellful Co.,Ltd. (Shanghai Stock Exchange: 600975.SS) is a leading Chinese manufacturer and supplier of pharmaceutical preparations and medical devices, specializing in oncology, anti-infection, and nervous system therapeutics. The company offers a diverse portfolio of products including small-volume injections such as irinotecan hydrochloride for colorectal cancer treatment; tablets and capsules like entecavir for hepatitis B; and medical devices encompassing infusion sets, syringes, and blood bags, marketed under brands like New Wellful and Wellful. Founded in 1958 and headquartered in Xiangtan, Hunan province, it operates primarily in China with distribution networks serving hospitals, pharmacies, and healthcare institutions nationwide. In recent developments, Hunan New Wellful expanded its production capacity through a major green manufacturing project completed in 2024, enhancing output for key oncology drugs amid rising demand. The company formed strategic partnerships with leading pharmaceutical distributors in 2025 to bolster market penetration in tier-2 and tier-3 cities, while launching new formulations of piperacillin sodium tazobactam for anti-infection applications. Additionally, it pursued R&D collaborations with academic institutions for innovative drug delivery systems, positioning itself for growth in the competitive domestic biopharma sector.